Report initial data from two Phase 1b/2 studies for DISC-0974

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 11 Aug 2023
Due: 31 Dec 2023
Delivered: December 2023

Deadline
Met
Late
Not met
Today

What the company said

“initial data from both trials expected by year-end 2023”

SourceDisc Medicine, Inc. Form 8-K press release, 2023-08-11
FilingSEC filing index
Deadline as statedyear-end 2023
Deadline used31 Dec 2023, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2023-IRON-002148
Cite as https://keptindex.org/c/KI-C-2023-IRON-002148/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company reported interim data from both Phase 1b/2 clinical trials for DISC-0974 in December 2023, meeting the year-end 2023 deadline.

A
Disc Medicine, Inc. 10-K filed 2024-03-21 Regulatory filing · published 21 Mar 2024 · retrieved 1 Oct 2026 · kept permanently by the SEC
“We reported interim data from both of these studies in December 2023.” ✓ confirmed on the page
A
Disc Medicine, Inc. 10-Q filed 2024-05-09 Regulatory filing · published 9 May 2024 · retrieved 1 Oct 2026 · kept permanently by the SEC
“We also announced updated data from our Phase 2 BEACON clinical trial of bitopertin and initial data from our Phase 1b/2 DISC-0974 trials in patients with anemia of MF and patients with anemia and NDD-CKD in December 2023.” ✓ confirmed on the page

Market reaction: the shares moved -10.3% against the S&P 500 over the three sessions around the disclosure (20 Mar 2024 to 25 Mar 2024). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +731 days
2 versions

Version 1 · original · stated 11 Aug 2023

Deadline 31 Dec 2023 (“year-end 2023”) · wording expected
Version 2 · stated 10 Jan 2025

Deadline 31 Dec 2025 (“H2 2025”) · wording expected

“Initial data from an ongoing phase 2 study of DISC-0974 (anti-hemojuvelin antibody) in anemia of myelofibrosis (MF) expected H2 2025”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: DISC-0974 Phase 1b/2 trial data
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.